UBS reiterated a Buy rating on Jazz Pharmaceuticals on July 2, 2025.

The entities involved

• Jazz Pharmaceuticals →

  Irish tax-registered pharmaceutical corporation

  • Jazz Pharmaceuticals plans U.S. launch of Ziihera.Wed 22:28
  • Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.Wed 13:55
• UBS →

  Swiss multinational investment bank and financial services company

  • The Trump administration threatens tariffs on Switzerland, leading Switzerland to seek a new trade agreement with the US.Mon 00:13
  • Following the acquisition of Credit Suisse, the Swiss parliament proposed new banking regulations for UBS.Sun 10:25

Related events

• Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.Aug 26
• The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.Sep 11
• Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.Sep 4
• Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.Aug 31
• UBS analyst maintained a Buy rating on Applied Materials stock.Aug 26